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Abstract
Background: Studies suggest that the process of patient consent to clinical trials is sub-optimal.
Participant information sheets are important but can be technical and lengthy documents.
Performance-based readability testing is an established means of assessing patient information, and
this study aimed to test its application to participant information for a Phase 3 trial.
Methods: An independent groups design was used to study the User Testing performance of the
participant information sheet from the Phase 3 'Poor Responders' trial of In Vitro Fertilisation (IVF).
20 members of the public were asked to read it, then find and demonstrate understanding of 21
key aspects of the trial. The participant information sheet was then re-written and re-designed, and
tested on 20 members of the public, using the same 21 item questionnaire.
Results: The original participant information sheet performed well in some places. Participants
could not find some answers and some of the found information was not understood. In total there
were 30 instances of information being not found or not understood. Answers to three questions
were found but not understood by many of the participants, these related to aspects of the drug
timing, Follicle Stimulating Hormone and compensation. Only two of the 20 participants could find
and show understanding of all question items when using the original sheet. The revised sheet
performed generally better, with 17 instances of information being not found or not understood,
although the number of 'not found' items increased. Half of the 20 participants could find and show
understanding of all question items when using the revised sheet. When asked to compare the
versions of the sheet, almost all participants preferred the revised version.
Conclusion: The original participant information sheet may not have enabled patients fully to give
valid consent. Participants seeing the revised sheet were better able to understand the trial. Those
who write information for trial participants should take account of good practice in information
design. Performance-based User Testing may be a useful method to indicate strengths and
weaknesses in trial information.
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Background
Over the past decade writers have expressed concern
about the process of consent to clinical trials and the lev-
els of knowledge about the trial that participants have.
Three surveys of patients' understanding at the end of a
trial have found sub-optimal comprehension, such as one
fifth not knowing the name of the medicine being tested
[1] and 30-40% patients not knowing that they could
withdraw from the trial at any time [2,3]. A study of
healthy trial volunteers reported that almost all partici-
pants could recall the procedure being researched, but
only a small minority could recall drugs used in the trial
or potential side effects [4]. This finding of variable
knowledge is confirmed by a systematic review of com-
munication and informed consent in cancer trials. [5] It
suggested that aspects such as risks and benefits associated
with the tested medicine and the right to withdraw con-
sent, were understood less well than others. The review
concluded that "patients do not appear to be adequately
informed of the aims of (Phase 1) trials" (p.304).
There can be many reasons for a lack of knowledge: infor-
mation sheets may be too long or too complex [4,6], or
the recruiting clinician might not check patient under-
standing [7]. Furthermore, levels of knowledge may vary
according to participant characteristics. For example,
understanding of trials was shown to be poorer among
older patients and those with fewer years in education [8].
Finding a low level of knowledge of aspects of the trial
might question the extent to which consent was valid or
informed. It might also impact on the running of the trial.
One study found higher levels of "later decisional regret"
among trial participants who thought they had been less
informed about their decision to participate [9].
The concern about participant understanding was height-
ened as a result of the serious adverse events among
healthy volunteers in the TGN1412 Phase I trial in 2006.
The Expert Scientific Group, formed as a result of the inci-
dent, reported that the process of informed consent and
clarity of participant information were "extremely impor-
tant" and should be "taken up as a high priority and con-
sidered in detail" [10]. The Royal Statistical Society report
criticised the TGN1412 information sheets, particularly
for the way that the treatment allocation schedule was
explained, and the use of difficult, technical words [6].
The participant information sheet performs different pur-
poses before and after consent is taken. Pre-consent the
sheet is used, along with spoken information from the
recruiting clinician, to explain the trial: its purpose; what
consent means; the tested medicine; and, the patient's
responsibilities. The sheet can also help the patient to for-
mulate questions.
Post-consent the sheet's functions are slightly different. It
serves to remind the patient of what they have agreed to,
and it can also act as a memory aid on particular aspects
of the trial. After consent the patient needs to be able to
understand the sheet without access to a clinician. This
last point emphasises the need for the sheet to be written
and presented such that participants can find and under-
stand information. The role of the participant informa-
tion sheet would seem to be particularly important in
studies of complex interventions, such as in In Vitro Ferti-
lisation (IVF), when different medicines are administered
for varying lengths of time throughout.
One method for assessing readability is the use of formu-
lae [11-13]. These tests can be used to assess any written
document, including trial information. One review of
information sheets by readability formulae suggests that
most require too high a standard of literacy in readers
[14]. Formulae are often used by US Institutional Review
Boards, who require that sheets score at a certain level of
readability, before approving a trial [15].
Readability formulae can be easily used, and the gener-
ated score largely depends on word and sentence length.
A major weakness is that they cannot assess the meaning
of information - the phrase "injection by given be will medi-
cine the" will attain the same readability score as "the med-
icine will be given by injection" - and, perhaps more
importantly, they cannot indicate how the information
will perform. For example, they cannot show whether
patients will understand safety issues, or procedures, or
randomisation. The limited value of formulae has led to
recommendations to test participant information sheets
by their performance [16,17]. Recent performance-based
testing of a Phase I trial sheet found significant readability
problems. The study also reported an improved level of
performance after the sheet had been re-worded and re-
designed [18].
Testing the performance of patient information is rela-
tively recent [19] and it has gained impetus since Euro-
pean law has required medicine manufacturers to test the
patient information leaflets supplied with every licensed
medicine [20]. Market authorisation for a new drug will
not be granted until a successful, documented test has
been conducted. As a consequence, since 2005 medicine
leaflets across Europe, including several thousand in the
UK, have been tested for readability using a performance-
based method. In almost all cases the method used has
been 'User Testing', as described in guidance documents
[21]. User Testing involves potential medicine users read-
ing the information, and then being asked to find and
show understanding of 12-15 items of information. (The
term 'User Testing' can be misunderstood - it is the users
who are testing the information, rather than the usersTrials 2009, 10:79 http://www.trialsjournal.com/content/10/1/79
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being tested.) Participants are usually potential users of
the information, rather than those currently taking the
medicine, whose prior knowledge might bias results. User
Testing is intended to be iterative, with the information
being revised after rounds of 10 participants, to remedy
any identified flaws. The EU legislation requires that the
final version of the leaflet should have been tested on two
rounds of 10 people, and that each can be found and
understood by at least 8 of every 10 people [20,21]. Since
the 1990s User Testing has been applied to medicine leaf-
lets in Australia [22].
Several studies have examined the effect of making
changes to trial participant information sheets. Shorten-
ing the information about an asthma trial led to greater
understanding of a number of aspects (including ran-
domisation, duration, and benefits) [23]. Re-writing par-
ticipant information into an 'easy-to-read' format led to
greater satisfaction and less anxiety among participants
[24], although understanding of the information was not
assessed. However, one study found no effect of offering
different explanations of aspects of trials, such as equi-
poise and random allocation [25].
This paper reports the User Testing method in relation to
the participant information used in the 'Poor Responders'
IVF trial [26], a trial with relatively complex interventions.
It assesses whether people could find and understand key
pieces of information related to the trial. The test results
are then used to inform the revision of the participant
information sheet.
Methods
Design
An independent groups design was used, with each partic-
ipant seeing only one version of the information.
Participants
40 healthy members of the public were recruited via news-
paper advertising and promotional flyers distributed to
houses and businesses in the local area. They had been
recruited to take part in readability studies. We also
approached fertility and IVF support groups in the area, in
order to recruit women with personal experience of IVF.
Participants were adult women aged under 45, as in the
actual 'Poor Responders' IVF trial. We excluded women
who had taken part in any medicine trial or readability
testing study in the previous 6 months. In addition we
ensured that each round of 10 participants had a similar
profile in terms of likely influences on testing: age, educa-
tion and occupation. We also ensured that each round
contained a similar number of women who had them-
selves received IVF treatment, in case their experience
influenced understanding of the trial information.
Tested Materials
(i) The original 'Poor Responders' trial participant
information sheet, comprising 7 pages of single-sided
A4 paper (see Figures 1 and 2 for example sections).
This was obtained from the article reporting the trial
methods [26]. We contacted the authors to inform
them that we intended to test the trial information
sheet for readability, and asked them to confirm how
it was presented to potential participants. Before test-
ing all content identifying individuals or organisations
was replaced with pseudonyms.
(ii) A revised version of the 'Poor Responders' trial
sheet, retaining its meaning but with revised format,
appearance and wording. See below for further detail
on this revision process (and see Figures 3 and 4 for
example sections).
Outcomes
Participants' ability to find 21 key points of information
in the sheets, and then convey their understanding of each
of those points (see Table 1). The 21 items were drawn
from four categories of information, being those that
would apply to trials of any phase:
• the nature and purpose of the trial (2 questions);
￿ the process and meaning of consent (7);
￿ trial procedures (8);
￿ safety and efficacy of the tested medicine (4).
We identified the four categories as being those that all
clinical trial sheets would contain. The complex nature of
IVF treatment meant that the questionnaire in this study
featured more questions on trial procedures than were
included in the testing of a Phase 1 trial sheet [18]. Con-
versely, the Phase I sheet testing questionnaire included
more items on the safety and efficacy of the trial medicine.
The authors independently selected the 'key points' for
questions, based on the pre-defined categories, with any
differences reconciled by consensus. The questionnaire
was then written, based on the selected items of informa-
tion. As is normal practice in User Testing, questions were
arranged so that their order did not correspond with the
order of the information in the sheet. The questionnaire
was piloted on 2 participants and we subsequently made
minor wording changes. During testing each of the 21
items was scored for finding information: yes, no, or found
with difficulty (i.e. taking more than 3 minutes) and, if
found, scored for understanding (yes or no).Trials 2009, 10:79 http://www.trialsjournal.com/content/10/1/79
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Front page of the original participant information sheet Figure 1
Front page of the original participant information sheet.
Newland Hill NHS Foundation trust, 
Assisted Conception Unit, 
Newland Hill Hospital, 
London, NW16 7BJ. 
Tel 01234 149688 
Fax 01234 149655 
Date Created  05/12/06  Review Date  05/12/07  Version no  2 Page 1 of 7 
Poor Responders revised 2 Author: SK  Stoke  Authorised: Y. Prestwich 
Poor Responders Intervention Trial 
PARTICIPANT INFORMATION SHEET 
You are being invited to take part in a research study. Before you make your decision, it 
is important for you to understand why the research is being done and what it will 
involve. Please take time to read the following information carefully. You may want to 
talk to others about the study before taking part. 
Part 1 tells you the purpose of this study and what will happen to you if you take 
part. 
Part 2 gives you more detailed information about the conduct of the study.
Ask us if there is anything that is not clear or if you would like more information. Take 
time to decide whether or not you wish to take part.  
Part 1
What is the purpose of the study? 
There are three commonly used regimens used to suppress the pituitary hormones 
during In Vitro Fertilisation (IVF). The purpose of this research is to find out which of 
these is the most effective for women who have shown a poor response in their previous 
treatment cycle(s). There is currently no evidence to say which gives the best outcome. 
It is necessary during IVF treatment to control the reproductive cycle. In order to do this 
drugs are used to suppress the reproductive hormones released by the pituitary gland in 
the brain. These hormones are the Follicle Stimulating Hormone (FSH) and the 
Luteinising Hormone (LH). Both these hormones are stimulated by the Gonadotrophin 
Releasing Hormone (GnRH). 
There are two types of drugs which suppress the pituitary hormones. The first is a GnRH 
agonist, called Nafarelin. An agonist is a drug which mimics the action of a naturally 
occurring substance in the body. Nafarelin activates the pituitary just like the GnRH in 
the body, but while the GnRH triggers the release of hormones by repeated on/off 
pulses, Nafarelin in IVF treatment delivers a long, sustained burst which keeps the 
pituitary in the ‘off’ mode. 
The second drug is a GnRH antagonist, called Cetrorelix. An antagonist is a drug which 
opposes the action of a naturally occurring substance in the body. In this way, Cetrorelix 
prevents the release of pituitary hormones.  Trials 2009, 10:79 http://www.trialsjournal.com/content/10/1/79
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Treatment timeline as described in the original participant information sheet Figure 2
Treatment timeline as described in the original participant information sheet.
Date Created  05/12/06  Review Date  05/12/07  Version no  2   Page  2 of 7
Poor Responders revised.docx Author: SK  Stoke    Authorised: Y Prestwich 
There are three different regimes used to block the release of the reproductive 
hormones. They are as follows: 
1.  The GnRH agonist (Nafarelin) long regimen  
•  Day 21 of menstrual cycle: start Nafarelin nasal spray (continued until HCG 
injection) 
 approx 2 weeks later 
•  Ovarian stimulation with FSH injections (continued until HCG injection) 
 approx 9-14 days later 
•  HCG injection (to mature the eggs) 
 36 hours later
•  Egg collection * 
 2, 3, or 5 days later 
•  Embryos put back into the womb  
 2 weeks later 
• Pregnancy  test 
•  *Starting on the day of egg collection, you will take a daily dose of Progesterone 
(to prepare the lining of the womb), which is taken in the form of pessaries 
inserted into the vagina. These should be taken daily up until the pregnancy test. 
If the test is positive, the pessaries should be continued until the 8
th week of 
pregnancy.
• The approximate duration of this treatment regimen (from the start of Nafarelin  
until the pregnancy test is performed) is 6 weeks.  
2.   The GnRH agonist (Nafarelin) short regimen  
•  Day 2/3 of menstrual cycle: Start Nafarelin nasal spray (continued until HCG 
injection)  
•  Day 3/4: Ovarian stimulation with FSH injections (continued until HCG injection)  
 approx 9-14 days later
•  HCG injection (to mature the eggs) 
 36 hours later
•  Egg collection * 
 2, 3, or 5 days later 
•  Embryos put back into the womb  Trials 2009, 10:79 http://www.trialsjournal.com/content/10/1/79
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Front page of the revised participant information sheet Figure 3
Front page of the revised participant information sheet.
EV\Z&d[-
HijYnd[>K;IgZVibZcih[dg
LdbZcl]ZgZEgZk^djh>K;
]VhcdiWZZcHjXXZhh[ja
EVgi^X^eVci>c[dgbVi^dcH]ZZi
=dlidXdciVXijh
>[ndj]VkZVcnfjZhi^dch
VWdjii]^hhijYn!eaZVhZiVa`id
i]ZYdXidghl]ddg\Vc^hZ^i/
9gHid`ZdgBgEgZhil^X]dc
%&'()&).+--#
8dciZcih
&L]nVgZlZYd^c\i]^h
hijYn4
'L]ViYd>cZZYid`cdl
VWdjii]ZbZY^X^cZhjhZY^c
i]^hhijYn4
(L]nVb>WZ^c\Vh`ZYid
iV`ZeVgi4
)L]Vil^aa>cZZYidYd^[>
iV`ZeVgi4
*Edhh^WaZh^YZZ[[ZXih
+BdgZ^c[dgbVi^dcVWdji
iV`^c\eVgi
,=dlidXdciVXijh
LZ^ck^iZndjidiV`ZeVgi^cVgZhZVgX]
hijYn#
 7Z[dgZndjYZX^YZl]Zi]ZgidiV`ZeVgi!^i^h^bedgiVci[dg
ndjidjcYZghiVcYl]ni]ZgZhZVgX]^cWZ^c\YdcZVcY
l]Vi^il^aa^ckdakZ#
 EaZVhZiV`Zi^bZidgZVYi]Z[daadl^c\^c[dgbVi^dc
XVgZ[jaan#9^hXjhh^il^i][g^ZcYhVcYgZaVi^kZh^[ndjl^h]#
 NdjVgZ[gZZidYZX^YZl]Zi]ZgdgcdiidiV`ZeVgi^ci]^h
ig^Va#>[ndjX]ddhZcdiidiV`ZeVgi!i]^hl^aacdiV[[ZXii]Z
XVgZndj\Zi[gdbndjgdlcYdXidgh#
 6h`jh^[i]ZgZ^hVcni]^c\i]Vi^hcdiXaZVgdg^[ndjldjaY
a^`ZbdgZ^c[dgbVi^dc#
>bedgiVcii]^c\hi]VindjcZZYid`cdl
 LZlVciidÒcYi]ZWZhilVnidigZVildbZcl]d]VkZ
cdigZhedcYZYlZaaidegZk^djh>K;#
 LZVgZiZhi^c\i]ZjhZd[ildY^[[ZgZcibZY^X^cZhVheVgi
d[>K;igZVibZci!l]^X]VgZCV[VgZa^cVcY8ZigdgZa^m#
 CV[VgZa^cXVcWZjhZY^cildY^[[ZgZcilVnh!hdi]ZhijYn
]Vhi]gZZY^[[ZgZci\gdjehdgigZVibZcidei^dch#
 DcZbZY^X^cZjhZY^ci]ZhijYnXVcXVjhZh^YZ"Z[[ZXih!
Wjii]ZnVgZh]dgia^kZY#
 I]^hhijYnÒih^cidndjgcdgbVaigZVibZci!hdi]ZgZVgZcd
ZmigVXa^c^Xk^h^ihdghXVch#
 NdjYdcdi]VkZideVn[dgCV[VgZa^cdg8ZigdgZa^m!Wjii]Z
di]ZgbZY^X^cZhjhZY^c>K;bVn]VkZidWZeV^Y[dg#
 NdjXVchideiV`^c\eVgi^ci]ZhijYnViVcni^bZ#
Newland HillTrials 2009, 10:79 http://www.trialsjournal.com/content/10/1/79
Page 7 of 15
(page number not for citation purposes)
Treatment timeline as described in the revised participant information sheet Figure 4
Treatment timeline as described in the revised participant information sheet.
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Table 1: Testing results of the original and revised versions of the participant information sheets
Rounds 1 & 2: Original 
sheets (n = 20)
Rounds 3 & 4: Revised 
sheets (n = 20)
Found 
(of which, found with 
difficulty)
Understood Found 
(of which, found with 
difficulty)
Understood
Nature and purpose of the trial
Q1 Who is funding this trial? 20 (0) 20 20 (0) 20
Q2 What is the purpose of this trial? 20 (2) 18 20 (1) 17
Process and meaning of consent
Q4 What would happen to any information collected 
from you as part of the trial?
20 (4) 17 20 (2) 18
Q6 How is it decided which participants receive which 
treatments in the trial?
20 (1) 20 20 (0) 19
Q11 Suppose you joined the trial and then decided to 
drop out. What do the sheets tell you about that?
20 (0) 20 20 (0) 20
Q12 What does it say about who might benefit from 
you taking part in this study?
20 (1) 20 20 (0) 18
Q14 Would you have to pay for any of the medicines 
used?
20 (0) 20 20 (0) 20
Q15 Suppose you are harmed by taking part in the 
trial. What does the sheet say about compensation?
20 (0) 14 20 (0) 18
Q19 What does the information sheet say about how 
the doctors identify which patients should take part in 
the trial?
20 (1) 19 17 (0) 17
Trial procedures
Q3 If you took part in the study, would you have to 
make any additional visits to the hospital?
19 (1) 19 19 (0) 19
Q7 Suppose you took part in the trial and you needed 
to speak to a doctor urgently one evening. What 
number should you ring?
20 (1) 20 20 (0) 20
Q9 Suppose you took part in the trial and were in the 
Nafarelin short treatment group. When would you 
start to use the nasal spray?
20 (0) 20 20 (0) 19
Q10 What do the sheets say about taking 
Progesterone during the trial?
20 (0) 20 19 (1) 19
Q13 Suppose you are allocated to be in the Cetrorelix 
treatment group in the trial. What does it say about 
how and when Cetrorelix would be given to you?
20 (1) 15 20 (0) 19
Q16 Imagine you are in the Nafarelin long treatment 
group. How much time is there likely to be between 
starting the nafarelin and having a pregnancy test?
20 (0) 20 20 (0) 20Trials 2009, 10:79 http://www.trialsjournal.com/content/10/1/79
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Participants' evaluative comments on the participant
information sheets were recorded, as was the time taken
to read the information sheet and the time taken for the
structured user testing questions.
Procedure
The study comprised three stages:
(i) Testing of the original information sheet. The informa-
tion was tested using participants who were asked to
imagine receiving IVF treatment. They were asked to
imagine that they had been asked to take part in a trial
to test different ways of giving IVF. They were told that,
after having time to read the information through,
they would be asked some questions about it. They
were left alone to read the sheets and were asked to tell
the interviewer when they had finished reading. Then
each of the 21 User Test questions was put in turn and
the participant was asked, first, to find the answer in
the sheet and, second, to give their answer and, where
required, to explain what the information meant. No
upper time limit was placed on answering each ques-
tion and the interviewer moved on only if the partici-
pant requested or when it became clear that they could
not find the answer. After the 21 structured questions
participants were asked for their general impressions
of the sheet, with particular focus on the appearance,
wording, print size, headings and organisation of
information. Interviews were audio recorded and tran-
scribed; participants' evaluative comments were ana-
lysed according to the headings above.
(ii) Re-wording and re-design of the Information Sheet.
Revision of the information was based on three
sources: participants' User Test questionnaire data and
their opinions on the information sheet; best practice
in information wording and design [24]; the authors'
experience and expertise in information writing and
design. Care was taken to retain the original meaning
of the information.
(iii) Testing of the revised Information Sheet (as per stage
(i)), followed by participants' evaluative comments.
After completion of the second and third rounds of
testing, participants were asked to briefly read a copy
of the original sheet and were asked which of the two
versions they preferred and why.
Data analysis
User testing data for the original and revised versions of
the sheet were analysed in several ways:
1. We examined the total number of question items that
were 'not found' or 'not understood' across the 20 partici-
pants who saw each version of the sheet.
2. We identified the number of question items that were
found and understood by less than 80% participants (to
Q20 When taking part in the trial, on each occasion 
when you have taken your medicine, what would you 
then need to do?
20 (1) 20 20 (1) 20
Q21 Suppose you were taking part and had a concern 
about the study. How should you contact the doctors 
in charge?
20 (0) 20 20 (0) 20
Safety and efficacy of the medicine
Q5 Please name the two drugs used in the trial that 
affect the pituitary or reproductive hormones.
20 (0) 20 20 (0) 19
Q8 What does the sheet tell you about Follicle 
Stimulating Hormone or FSH?
2 0  ( 0 )9 2 0  ( 2 )2 0
Q17 What does the information tell you about getting 
the side effects of hot flushes and night sweats?
20 (0) 19 20 (0) 20
Q18 How does the medicine Cetrorelix work on the 
body?
20 (0) 20 20 (1) 20
Total items NOT found (found with difficulty) 1(13)/420 5(8)/420
Total items NOT understood 30/420 17/420
Table 1: Testing results of the original and revised versions of the participant information sheets (Continued)Trials 2009, 10:79 http://www.trialsjournal.com/content/10/1/79
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reflect the threshold recommended in EU legislation on
testing of medicine leaflets).
3. We calculated a score for each participant (in the range
0-21) based on how the number of items that each partic-
ipant could both find and convey an understanding of.
4. We assessed the proportion of participants who were
able to find and show an understanding of all 21 question
items.
The data for total question items and individual partici-
pant scores for the two sheet versions were compared by
use of t-tests. The proportion of participants able to find
and understand all items were compared by use of the
Chi-square statistic.
5. Mean reading and question times were compared for
the two versions of the sheet by use of the t-test.
6. Participants' evaluative comments on the sheets were
transcribed in full and analysed qualitatively, with themes
generated according to common influences on document
appraisal, including appearance, layout, wording, use of
graphics. We looked for both consensus and contrasts in
views, and report these by using illustrative quotes (with
the participant's identifying number given in parenthe-
ses).
Research Ethics
Approval to conduct the study was granted by the Univer-
sity of Leeds, School of Healthcare Research Ethics Com-
mittee in April 2008.
Results
Original information sheet (see Figures 1 and 2)
Quantitative data
The original information was tested on two rounds of 10
participants. The data from the first round of ten partici-
pants identified some problems with the readability of the
information sheet that we wished to confirm with a sec-
ond round. The 20 women were aged 23-44 (mean 34.3,
median 36 years) and ten had personal experience of IVF
treatment. Of the twenty participants, nine were higher
education graduates, and eight were unemployed or had
occupations that did not involve regular use of written
documents.
Participants took a mean of 11.9 minutes (range 4 - 22,
median 10 minutes) to read the sheet. The period taken to
complete the 21 structured questions was a mean of 25.5
minutes (range 14.5 - 45.2 minutes, median 24.4 min-
utes).
Table 1 shows that participants took a long time to find
several answers, as indicated by 'difficulty' ratings (see
Table 1). Answers to three of the 21 questions were found
and understood by fewer than 80% of the 20 participants.
These questions related to:
￿ FSH, one of the hormones affected by the tested medi-
cines (Q8);
￿ How and when the tested medicine will be given (Q13);
and
￿ Compensation in case of injury (Q15).
In total 30 (of 420) question items were not understood
by participants. When assessing data at a participant level,
the 20 participants were able to find and show under-
standing of a mean of 19.5 items (range 18 - 21). Only 2
of the 20 participants were able to find and show under-
standing of all 21 question items.
Qualitative data
Participants' comments on the sheet were mixed. One
positive feature was noted to be the print size, with only 2
of the 20 participants suggesting that it should be larger.
For the most part the language was thought to be clear,
although some participants struggled to understand the
medical terms:
"We've got a lot of long words here...but I don't think it's
too baffling" (P3);
"The technical terms are a bit hard to understand" (P6);
"It's a bit confusing to work out which drug's having what
effect on the body" (P17).
The organisation of the information was thought to be
problematic. Two features mentioned by several partici-
pants were the opening page:
"I'd probably like to know why the study is taking place and
who is to benefit on the front or second page" (P9);
"There should be more information about what's involved
in taking part in the study at the beginning...it launches
into quite scientific explanations" (P13)
and some repetition:
"The 'do I have to take part?' bit and...'what will happen if
you decide to pull out' I don't think is needed to be in twice"
(P11).
The appearance of the sheet was mostly seen positively,
including  "professional"  (P8),  "neat and tidy" (P6),
although one participant found the spacing to be "...a bit
random...a bit rushed" (P9).Trials 2009, 10:79 http://www.trialsjournal.com/content/10/1/79
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When asked for general impressions, comments were split
between those who were positive ("quite thorough" (P7);
and "informative" (P16)) and those who found it generally
difficult ("I don't think it was clear" (P2); "It does sound a bit
confusing" (P5); and "it doesn't really make sense" (P10)).
Others were critical of particular aspects:
"It's quite confusing to begin with all the FSH, GnRH and
so on" (P16);
"I found totally confusing the first three pages" (P3);
"(the flow diagram) is a little bit misleading" (P15).
Finally, the name of the trial was criticised, including:
"It's a strange name for the trial. It makes it sound like
you've done something not very well" (P19), and
"(the name)...isn't particularly positive" (P15).
The problems noted in finding and understanding scores,
the time taken to answer questions, and participants'
comments all indicated that the original information
sheet was not performing well. This meant that revision of
the information was required, followed by further rounds
of testing.
Revised information sheet (see Figures 3 and 4 for 
examples)
The information sheet was revised and used Linotype Fru-
tiger Next font and presented as a folded booklet of A4
size. Changes to the sheet included:
￿ Adding to the front page: a brief table of contents and a
summary of the most important points;
￿ Amending the title of the trial;
￿ Introduction section headings;
￿ Increased size of page numbers;
￿ Shortened sentences (where necessary);
￿ Use of lay language;
￿ Increasing the font size and removing occasional italics;
￿ Giving greater emphasis to the contact telephone num-
bers and placing them on both first and last pages;
￿ Use of 'bullets' for lists;
￿ Adding a graphic to illustrate the timing of the various
processes, for each of the three trial arms;
￿ Use of colour for the section headings and the graphic.
The revised information was tested on two rounds of 10
female participants. The data from the first round of 10
participants for the revised sheets showed that it was per-
forming generally well. We tested the sheets on a second
round of 10 participants to confirm the data pattern. The
20 participants were aged in the range 23-41 (mean 33.5,
median 34.5 years), ten of whom had personal experience
of IVF treatment. Nine of the 20 participants were higher
education graduates, and eight participants were unem-
ployed or had occupations that did not involve regular use
of written documents.
Quantitative data
The 20 participants took a mean of 10.4 minutes (range 3-
16, median 9.5 minutes) to read the document, a little
quicker than for the original document (but the difference
is not statistically significant: t = 0.791; p = .44; 95% CIs
of the difference -2.48 to 5.48). The period taken for the
21 structured questions was a mean of 20.1 minutes
(range 15.7 - 26.0, median 19.5 minutes), a mean reduc-
tion of around 5 minutes when compared to the original
version (but the difference is not statistically significant: t
= 1.875; p = .077; 95% CIs of the difference -0.65 to
11.51).
The problems that participants faced with answering
questions 4, 8, 13 and 15 from the original sheet had been
rectified. Some minor problems continued, particularly
with questions 2 (trial purpose) and 19 (patient identifi-
cation), but it was felt that there was no easy solution in
terms of design or writing. However, all of the answers to
questions were found and understood by at least 80% par-
ticipants. Looking at aggregated data, the revised sheet
almost halved the number of items that were not under-
stood by participants: from 30 for the original sheet to 17
for the revised sheet (but the difference is not statistically
significant: Chi-square = 3.81; df = 1; p = .051). However,
the number of question items not found by participants
was 5 (of 420) for the revised sheet, an increase from 1 (of
420) for the original sheet. The difference is not statisti-
cally significant (Chi-square = 1.51; p = 0.22; Odds ratio
= 0.20; 95% CIs 0.02 to 1.70).
For data at the participant level, the 20 participants were
able to find and show understanding of a mean 20.4 items
(range 16 - 21), a mean increase of around 1 item when
compared with the original sheet. The difference is statis-
tically significant (t = 2.59; p = .019; 95% CIs of the differ-
ence 0.17 to 1.63).Trials 2009, 10:79 http://www.trialsjournal.com/content/10/1/79
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Ten of the 20 participants were able to find and show
understanding of all 21 question items, a large increase
from 2 (of 20) participants for the original sheet version.
The difference in proportions is statistically significant
(Chi-square = 5.83; p = .006; Odds ratio = 9.0; 95% CIs
1.64 to 49.4).
Qualitative data
Participants' comments about the revised sheet were
mostly favourable, including its appearance:
"It doesn't look like it's a scary thing to read" (P40);
"It's relatively appealing. I've seen others where it's just
block text" (P26), and
"It looks...like a leaflet you'd want to pick up and read"
(P37).
The timelines graphics, headings and contents listing were
particularly praised:
"it's nice that there's a graph or timeline as well" (P32);
"I answered from there (the timeline) instead of looking in
the other stuff. That was really easy to understand in the
stages of what went on" (P33);
"(The timelines) worked really well because they tell you
exactly the stages" (P27);
"I think (the headings) are all fine because they are all
important questions if anyone was doing the trial they'd
want to know. They are all on the contents page at the
front" (P21); and
"If you look on the front and you need to find out where
stuff is you go through each section and I think the headings
just sum up what's in it" (P33).
No participant felt that the print size was too small, and
the language used was mostly thought to be at the right
level for patients:
"It's not too technical which is pretty good because a lot of
words that are used in IVF can be" (P27);
"(There are) no huge big medical words there, they were
explained in laymen's terms" (P28).
However, some participants found the regimen explana-
tions difficult:
"I found it a bit hard to be honest because I'm not very good
at things like that" (P37).
In general comments, participants found the sheet to be
"really straight forward." (P32), "really good...not too over
your head or in depth" (P28), and "quite self-explanatory"
(P40).
After reviewing the original information sheet, the 20 par-
ticipants were asked for their preferred version. The
revised version was preferred by 18 (90%) participants;
one preferred the original and one expressed no prefer-
ence.
The participant who preferred the original version of the
sheet thought that
"(It) seemed to flow...and there were quite large para-
graphs in this (revised version) one" (P38).
Whereas the participant who could not express a prefer-
ence said:
"If I was paying for my own treatment I may prefer (the
original version) because I may think that all my money is
going to produce glossy pamphlets like (revised version), but
in terms of being easier to work your way through (revised
version) is better" (P31).
Among the 18 participants who preferred the revised ver-
sion, reasons included problems with the original ver-
sion's layout:
"The layout of it is a bit poor because it's text heavy on one
page" (P21);
"It sort of blends into one because you've got the long treat-
ment and the short treatment on the same page you're hav-
ing to flip over" (P23);
"The way it is laid out is very intimidating" (P26); and
"It makes me, my brain want to shut down straight away"
(P25).
The title was also not liked:
"it says 'poor responders' which may make you feel
depressed" (P26);
"(It's) not a good title to have on the document for people
who have been unsuccessful, I don't think that's a very sen-
sitive title to have" (P30).Trials 2009, 10:79 http://www.trialsjournal.com/content/10/1/79
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By comparison, the revised version was thought to have a
better appearance:
"More professional...more like a patient information leaflet
you'd pick up in hospitals" (P22);
"It makes you feel like it's not just come from a printer, it's
been produced with a lot of thought and care" (P24);
"The look, it seems clear, each heading in bold print so you
know where to look for certain points...the fact that it's got
colour helps" (P36); and
"You're attracted to read it from cover to cover" (P40).
The appearance of the revised sheet was also thought to
have an impact on the appeal and readability of the infor-
mation the sheet contains:
"Possibly it seems like there is less information in (revised
version) but I think actually it gives you more. Because of
the way it's laid out you pick up more" (P22); and
"It looks easier to follow and understand. The writing's
spread out more. This (original version) looks like too much
information, this (revised version) doesn't." (P35).
Discussion
Performance-based readability testing of the participant
information sheet for the 'Poor Responders' trial showed
that it performed sub-optimally. Members of the public
took a long time to find some aspects of the trial. When
information was found, it was not always understood.
Three important aspects of the trial were not understood
by five or more of the 20 participants. Revising the docu-
ment - by re-writing and re-designing it, while retaining its
meaning - led to improvements in its performance. In par-
ticular, almost all the found information was understood
correctly.
The original sheet performed well in some places and par-
ticipants were able to find and understand an average of
19.5 items (not far below the 'ceiling' of 21 items). Sheet
revisions increased the mean to more than 20. Sheets revi-
sions led to a fall in the number of 'not understood' items,
but an increase in the number that were 'not found',
showing a mixed effect of sheet revision. From a clinical
perspective, however, it is perhaps the increase in the pro-
portion of participants able to find and understand all
items that is most meaningful: this figure jumped from
10% to 50%.
In general, the results of this study support the views of
Ancker [17] and others that the analysis of the trial Partic-
ipant Information Sheet needs to be based on its perform-
ance, rather than on a number obtained from a readability
formula. For, at worst, documents can be manipulated to
perform better on readability formulae, with little or any
real change in the ease with which participants can use the
information. Readability formulae can give an indication
of the usability of a document, but they offer very limited
value in terms of indicating which aspects of a document
'work' and which do not. An alternative approach would
be to use a less structured method, with a focus on peo-
ple's opinions on a document. However, it is not clear
how closely people's opinions on a document match its
ability to inform, and we are aware of no studies that
make such a link.
As outlined previously, the sheet was revised with refer-
ence to three sources: best practice in information design
and writing; authors' expertise; and the data obtained
from the test of the original version. One pertinent ques-
tion is whether testing data are necessary, or whether a
document can be revised from expert knowledge and best
practice alone. A recent review of information design in
relation to medicines information [27] argues that the dis-
cipline is more than just a set of principles or rules for
good design; an analysis of the needs of information users
is also essential. The collection of testing data allows such
needs to be indicated. Published research also supports
the view that testing data are needed: experts are not good
at predicting the problems that readers will face when try-
ing to read and understand a document [28]. The revision
of the trial information in this study did make explicit ref-
erence to the participant data obtained; for example, the
inclusion of a revised timeline, an amended title, and re-
worded explanation of the drugs and hormones relevant
to IVF.
There are six questions (numbers 4, 5, 6, 10, 12 and 19;
see Table 1) where proportionally more people could not
find or understand information in the revised sheet than
in the original version. The increase in 'not found' items is
not statistically significant, and the differences may be due
to chance or to variation in participants between the 'orig-
inal' and 'revised' groups. We sought to match the groups,
and did so successfully, based on several relevant patient
characteristics. In the authors' experience it is unusual that
a document performs in User Testing such that all items
are 'found' and 'understood' by all participants - in this
study we were able to achieve 50% participants doing so.
The sheet for the 'Poor Responders' trial might have been
further revised and tested on additional rounds of partici-
pants, although it is questionable whether further
improvements in performance would have resulted.
Rather, the interpretation of User Testing data should
probably emphasise the pattern of scores obtained across
the questionnaire, and on this basis the revised informa-
tion performed well.Trials 2009, 10:79 http://www.trialsjournal.com/content/10/1/79
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The participants in this study were relatively well edu-
cated: the proportion of higher education graduates was
much higher than in the general population, for instance.
In part this is due to our aim that half the participants had
personal experience of IVF: these participants were
recruited via support groups that tended to have more
highly educated members. It would be important that
future studies of trial participant information sheets
include samples that more closely resemble the character-
istics of actual trial participants.
The User Testing scores obtained for the original trial
sheet would question whether a participant in this trial
would have been fully informed before giving consent,
particularly since just 10% participants could find and
understand answers to all questions. Furthermore, partic-
ipants would not have been able to use the sheet easily as
a resource, after giving consent and when away from the
hospital. This is important since research suggests that ver-
bal information alone will not be enough for many
patients; for example, most people quickly forget a third
to a half of the information they are given in a consulta-
tion [29,30].
The tested sheet was not particularly lengthy, certainly not
by comparison with many trial sheets, particularly those
used in Phase 1 trials. However, it did include technical
and complex information - both on the medicines and the
effect on the body, and the process and timing of using the
medicines. In testing of the original sheet even those par-
ticipants with personal IVF experience were among those
unable to answer questions 8 (on Follicle Stimulating
Hormone) and 13 (on dosage timing) correctly. Revision
of the sheet's wording and the addition of a graphic
resulted in this complex information being understood:
all 20 participants, including the 10 participants with no
personal experience of IVF, were able to understand the
information to answer those two questions.
Further evidence from medicine prescribing outside trials
is that patients prefer to receive information from clini-
cians in a spoken form; but they want written information
to complement it [31]. As stated earlier, the participant
information sheet could be seen to perform several func-
tions: pre-consent it informs and provokes questions;
post-consent it acts as a memory aid and a record for the
participant. The aspiration of health information design
and writing is that any document intended for the patient
should be good enough for them to read and understand
without the need to seek clarification. The User Testing
method evaluates the performance of written information
under such circumstances. Consent to clinical research,
including trials, is based on a combination of written
information in the form of a participant information
sheet and spoken information from a clinician. The data
in this study indicate the difficulty faced in writing com-
plex trial information such that participants can under-
stand it all: the complementary spoken information from
a clinician appears to be essential to clarify and explain.
The User Testing method uses small numbers of partici-
pants and so cannot give the statistical certainty of larger
quantitative research designs. Rather, it is a detailed and
iterative process, well established in the Information
Design domain [19]. When used in practice the main defi-
ciencies in a document can be identified after interviewing
just 10 potential users. However, it would require a study
comparing the original and revised versions, with random
allocation of participants, to confirm the pattern of scores
reported here. The process of revising the sheet by using
data from the testing of the original version, meant that it
was not possible to conduct the study with random allo-
cation to parallel groups. Larger scale research might
include sub-group analyses in order to answer important
questions including whether less educated participants
gain more benefit from the revision of information sheets
and, pertinent to this population, whether participants
with experience of IVF do better. The small sample
recruited here was appropriate for the study aims, since
User Testing can reveal most of the problems associated
with a document when tested on rounds of 10 or 20 par-
ticipants [19].
It is important to note that this study does not address the
appropriateness of the content of the original participant
information sheet: it simply shows that the wording and
layout of the original information were sub-optimal in
terms of patient understanding.
This study suggests that the materials provided for partic-
ipants in this trial might fail to inform them fully. The
'Poor Responders' trial information was not particularly
lengthy (sheets often run to 15 pages or more), and longer
trial sheets may well perform less well than this. We need
further research to indicate whether other examples of
trial information can be understood by potential partici-
pants.
Conclusion
User Testing can allow information to be evaluated in a
structured way. When it is combined with expertise in
writing for patients and information design, it may result
in a greater proportion of patients being able to under-
stand what will happen within a trial. Not only would this
impact on the extent to which valid consent is given, but
it may also impact on the smooth running of the trial,
with participants knowing where and when to take medi-
cines, return for tests, etc. Increasingly potential partici-
pants have been involved in the development of trial
materials, often resulting in the materials being alteredTrials 2009, 10:79 http://www.trialsjournal.com/content/10/1/79
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substantively [32]. The great strength of performance-
based testing is that it allows confirmation (or otherwise)
that such changes will be of benefit to participants.
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